A new development in metabolic medicine is arriving in the UAE, the Wegovy pill, an oral form of semaglutide designed for chronic weight management. Following its rollout in the United States, the Wegovy pill is expected to become available in the UAE in mid-2026 through a phased, physician-led launch and Metabolic will be the first clinic to get access to it.
Here’s what you should know.
What is the Wegovy pill?
The Wegovy pill is a once-daily oral medication containing semaglutide, a GLP-1 receptor agonist used in the treatment of obesity and overweight with related metabolic conditions.
It works by acting on appetite regulation pathways in the brain, helping reduce hunger and increase satiety, which may support sustained weight loss when combined with lifestyle changes.
Clinical trial results (what the data shows)
The Wegovy pill has been evaluated in large-scale clinical trials involving adults with obesity or overweight.
Key findings from a 64-week clinical trial:
- Average weight loss: ~13.6% of body weight vs 2–3% with placebo
- In some analyses, weight loss reached up to ~16–17% in patients who remained on treatment
- Around 1 in 4 patients achieved ≥20% weight loss
- It is easier to stay on compared to alternatives because the side effects were noticeably lower
These outcomes were observed alongside diet and physical activity guidance under medical supervision.
How is it taken?
The Wegovy pill is designed for simple daily use:
- Taken once daily in the morning
- On an empty stomach
- With water only
- At least 30 minutes before food, drink, or other oral medications
This timing is important for absorption and effectiveness.
Who is it for?
It is typically prescribed for adults who are:
- (need indication data)
Why is it significant?
The introduction of oral semaglutide is considered a meaningful step in metabolic care because it offers:
1. A non-injectable option
A daily pill may be preferred by patients who are hesitant about injections.
2. Established science
Semaglutide has been studied for years across multiple large clinical programs and real-world use.
3. Clinically meaningful weight loss
Trials show double-digit average weight reduction over 64 weeks, with a subset of patients achieving higher responses.
4. Cardiometabolic relevance
GLP-1 therapies are also being studied for broader effects on cardiometabolic risk factors such as waist circumference, blood pressure, and inflammation markers.
When will it be available in the UAE?
The Wegovy pill is expected to become available in the UAE around mid-2026, following its initial international rollout. Metabolic will be the first to get early access to it.
How can you access it?
Access will be prescription-based and initiated through a medical consultation. Click here to join the priority waitlist.
Wegovy price in UAE
Foundayo Strength | List Price |
17.2mg | 1599 |
14.5mg | 1599 |
9.0mg | 1412 |
5.5mg | 1115 |
2.5mg | 773 |
0.8mg | 773 |
Wegovy Pill For Sale in Dubai, UAE
- Availability expected from Mid June across the UAE.
- Contact us here to book your consultation to buy Wegovy Pill.